Who makes Placebo (for HGP0904)?

Placebo (for HGP0904) is developed by Hanmi Pharmaceutical Company Limited.

What development phase is Placebo (for HGP0904) in?

Placebo (for HGP0904) is in Phase 3.

Last reviewed 2026-04-23 · How we verify

Placebo (for HGP0904)

Hanmi Pharmaceutical Company Limited · Phase 3 active Small molecule

Placebo is an inert substance with no active pharmacological mechanism.

At a glance

Generic name	Placebo (for HGP0904)
Sponsor	Hanmi Pharmaceutical Company Limited
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Placebo serves as a control comparator in clinical trials and contains no active pharmaceutical ingredient. It is used to establish the baseline efficacy and safety profile of the investigational drug HGP0904 through comparison in randomized controlled studies.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Trial to Evaluate the Efficacy and Safety of HCP1302 (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Placebo (for HGP0904) CI brief — competitive landscape report
Placebo (for HGP0904) updates RSS · CI watch RSS
Hanmi Pharmaceutical Company Limited portfolio CI